ASTC - Astrotech Corporation
2.5200 +0.24 (10.53%)
After hours: 7:36PM EDT
| Previous Close | 2.6000 |
| Open | 2.4400 |
| Bid | 2.2500 x 1400 |
| Ask | 2.3100 x 1000 |
| Day's Range | 2.1800 - 2.4600 |
| 52 Week Range | 0.9800 - 7.7500 |
| Volume | 848,808 |
| Avg. Volume | 1,135,695 |
| Market Cap | 15.281M |
| Beta (5Y Monthly) | -0.14 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.2930 |
| Earnings Date | Feb 12, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.00 |
- Business Wire
Astrotech Announces Closing of $3.27 Million Registered Direct Offering Priced At-the-Market
Astrotech Corporation (NASDAQ: ASTC), today announced that it has closed its previously announced registered direct offering priced at-the-market of 873,335 shares of its common stock at a price of $3.75 per share for aggregate gross proceeds of approximately $3.27 million. The Company intends to use the net proceeds from this offering for continuing operating expenses and working capital.
- Business Wire
Astrotech Announces $3.27 Million Registered Direct Offering Priced At-the-Market
Astrotech Corporation (NASDAQ: ASTC), today announced that it has entered into definitive agreements with several institutional investors for the purchase and sale of 873,332 shares of Astrotech's common stock, at a purchase price of $3.75 per share, in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about March 31, 2020, subject to the satisfaction of customary closing conditions.
- Business Wire
Astrotech’s BreathTest-1000 Confirmed to Detect Lung Disease Metabolites at Parts Per Billion
Astrotech Corporation [NASDAQ: ASTC] announced that the BreathTest-1000™ lung disease screening device that is under development detects a known metabolite that is associated with lung diseases at very low parts per billion (ppb) concentrations. On March 25, the Company announced that it is working on developing the BreathTest-1000™ to detect volatile organic compound metabolites present in lung diseases such as the Coronavirus ("COVID-19") and pneumonia.
- Business Wire
Astrotech Announces Closing of $1.77 Million Registered Direct Offering Priced At-the-Market
Astrotech Corporation (NASDAQ: ASTC), today announced that it has closed its previously announced registered direct offering priced at-the-market of 354,000 shares of its common stock at a price of $5.00 per share for aggregate gross proceeds of $1.77 million. The Company intends to use the net proceeds from this offering for continuing operating expenses and working capital.
- American City Business Journals
Astrotech adapting bomb-sniffing tech to test for coronavirus
The Austin-based research and development company announced March 25 it is developing an instrument, called the BreathTest-1000, that would "screen for volatile organic compound metabolites found in a person’s breath" and identify if they are infected with COVID-19 or pneumonia.
- Business Wire
Astrotech Announces $1.77 Million Registered Direct Offering Priced At-the-Market
Astrotech Corporation (NASDAQ: ASTC), today announced that it has entered into definitive agreements with several institutional investors for the purchase and sale of 354,000 shares of Astrotech's common stock, at a purchase price of $5.00 per share, in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about March 27, 2020, subject to the satisfaction of customary closing conditions.
- MarketWatch
Astrotech's stock rockets 6-fold on heavy volume, as company develops breath test for lung infections
Shares of Astrotech Corp. were rocketed about 6-fold (up 496%) on very heavy volume in morning trading Wednesday, after the company said it was developing a breath test that could screen for lung infections, incoluding the COVID-19 virus. Trading volume was 23.3 million shares, compared with the full-day average of about 21,600 shares over the past 30 days. The stock had closed at a record low of $1.09 on Friday. The company's BreathTest-1000 is now under development; in June 2017, the company had announced "positive" results from preclinical trials of its BreathDetect-1000 bedside breathalyzer that detects bacterial infections in the respiratory tract, including pneumonia. Subject to regulatory approvals, the company plans to combine the detection of COVID-19 withthe detection of pneumonia into the BreathTest-1000. The stock has now rallied 76% over the past 12 months, while the S&P 500 has lost 12.3%.
- Business Wire
Astrotech Developing Screening Instrument for Lung Diseases Including COVID-19/Coronavirus & Pneumonia
Astrotech Corporation [NASDAQ: ASTC] today announced that the BreathTest-1000™ is under development to screen for volatile organic compound (VOC) metabolites found in a person’s breath that could indicate they may have an infection, including Coronavirus Disease 2019 ("COVID-19") or the resulting disease, pneumonia. The Company believes that its unique mass spectrometry technology that was initially developed in collaboration with the National Aeronautics and Space Administration (NASA), the U.S. Army, and the Transportation Security Administration (TSA) is ideal for lung disease testing applications, which are now under development.
- Business Wire
Astrotech Reports Second Quarter of Fiscal Year 2020 Financial Results
Astrotech Corporation (NASDAQ: ASTC) reported its financial results for the second quarter of fiscal year 2020, which ended December 31, 2019.
- Simply Wall St.
Those Who Purchased Astrotech (NASDAQ:ASTC) Shares Five Years Ago Have A 86% Loss To Show For It
It is doubtless a positive to see that the Astrotech Corporation (NASDAQ:ASTC) share price has gained some 37% in the...
- Simply Wall St.
Astrotech (NASDAQ:ASTC) Is Arguably In A Tricky Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
- Simply Wall St.
Is Astrotech Corporation's (NASDAQ:ASTC) CEO Paid At A Competitive Rate?
In 2007 Tom Pickens was appointed CEO of Astrotech Corporation (NASDAQ:ASTC). This report will, first, examine the CEO...
- Simply Wall St.
Could The Astrotech Corporation (NASDAQ:ASTC) Ownership Structure Tell Us Something Useful?
The big shareholder groups in Astrotech Corporation (NASDAQ:ASTC) have power over the company. Institutions will often...
